Search Results
Your search for ,New matches 16919 pages
Showing 3101 - 3150How the Pancreatic Cancer Early Detection Consortium Aims to Advance Survival Rates in This Deadly Disease
The statistics are grim: Worldwide, pancreatic cancer is the 12th most common cancer and the seventh leading cause of cancer mortality.1 In the United States, the malignancy has the highest mortality rate of all major cancers. It is currently the third leading cause of cancer-related death after...
Expert Point of View: Sophia C. Kamran, MD
Formal discussant of the PCS5 trial, Sophia C. Kamran, MD, Director of Diversity, Equity, and Inclusion, Department of Radiation Oncology at Massachusetts General Hospital and Assistant Professor of Radiation Oncology at Harvard Medical School, said the goal of trials like this one is to optimize...
PCS5 Trial: 5 Weeks of Radiation Therapy May Be Equivalent to 8 Weeks in High-Risk Prostate Cancer
According to the results of the phase III randomized Prostate Cancer Study 5 (PCS5), a noninferior trial, 5 weeks of radiation therapy may be equivalent to 8 weeks for men with high-risk prostate cancer on androgen-deprivation therapy. These findings were presented at the 2022 American Society for...
First-Line Ribociclib Plus Endocrine Therapy May Be More Effective Than Combination Chemotherapy in Patients With Aggressive Breast Cancer
In patients with hormone receptor–positive, HER2-negative advanced breast cancer—including patients with visceral crises—those treated with ribociclib plus endocrine therapy had fewer adverse events and significantly longer progression-free survival compared to those treated with combination...
Study Finds Racial Disparity in Prometastatic Tumor Microenvironment Among Patients With Residual Breast Cancer After Neoadjuvant Chemotherapy
Residual tumors from Black patients with estrogen receptor–positive/HER2-negative primary breast cancer treated with neoadjuvant chemotherapy had a higher risk score associated with a biomarker of distant metastatic recurrence compared with tumors from White patients, according to new findings...
Black Patients With Breast Cancer May Have Worse Outcomes Than Other Patients Despite Similar Genetic Recurrence Scores
Non-Hispanic Black patients with lymph node–positive, hormone receptor (HR)–positive/HER2-negative breast cancer experienced worse outcomes compared with the outcomes of non-Hispanic White, Asian, and Hispanic patients—despite similar 21-gene recurrence scores—according to new findings presented by ...
Lu-177 Vipivotide Tetraxetan Shows Benefit in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
On December 5, Novartis announced the pivotal phase III PSMAfore study of lutetium (Lu-177) vipivotide tetraxetan, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, met its primary endpoint. The therapy demonstrated a statistically significant and clinically meaningful...
ELIANA Trial 3-Year Update: Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed or Refractory B-Cell ALL
As reported in the Journal of Clinical Oncology by Laetsch et al, the 3-year update of the phase II ELIANA trial showed durable responses and a manageable safety profile with tisagenlecleucel for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute...
Risk of Cancer May Double for Patients With ‘Skewed’ Blood Cells
New research has shed light on how skewed X chromosome inactivation may be linked to the development of cancer and cardiovascular disease, according to a novel study published by Roberts et al in eLife. Background Because the X chromosome has so many more genes than the Y chromosome, in every cell...
Are Patients Older Than 65 Years Being Overscreened for Cervical Cancer?
Patients older than 65 years may be undergoing unnecessary cervical cancer screenings, and more public health data may be needed on the utilization of cervical cancer screening–associated services among older patients to prevent potential harm and unnecessary costs, according to a new study...
High Deductibles May Discourage Patients From Receiving Additional Testing After an Abnormal Mammogram
Twenty percent of patients are likely to forgo additional testing after an abnormal finding on a screening mammogram if there is a deductible, according to new findings presented at the Radiological Society of North America (RSNA) 2022 Annual Meeting. Background As health-care costs and insurance...
Does CBD Oil Improve Symptom Distress in Patients With Advanced Cancer Receiving Palliative Care?
In an Australian phase IIb trial (MedCan1-CBD) reported in the Journal of Clinical Oncology, Hardy et al found that use of cannabidiol (CBD) oil did not improve symptom distress vs placebo in adult patients with advanced cancer receiving palliative care. Study Details The double-blind multicenter...
Novel DELFI AI Blood Test May Aid in Detecting Hepatocellular Carcinoma
A novel artificial intelligence (AI) blood testing technology—known as DELFI (DNA evaluation of fragments for early interception)—may successfully detect more than 80% of hepatocellular carcinomas, according to a new study published by Foda et al in Cancer Discovery. The findings were also...
Novel Research Suggests New Way to Target Mantle Cell Lymphoma Using FOXO1 Inhibitors
Preclinical research has shown that mantle cell lymphoma is so critically dependent on the FOXO1 protein that by blocking its activity with an experimental drug, the cancer’s growth may be slowed, according to a new study published by Jang et al in the Journal of Clinical Investigation....
Kishu Ranjan, PhD, on Non–Small Cell Lung Cancer: New Findings on a Biomarker and Immunotherapy Resistance
Kishu Ranjan, PhD, of Yale University School of Medicine, discusses his study findings, which identified a deficiency in the biomarker TAP2 as a prominent immune evasion mechanism in patients whose non–small cell lung cancer has resisted immunotherapy (Abstract 148).
Study Examines Coping Strategies Used by Caregivers of Patients Undergoing Stem Cell Transplants
November is Caregiver Awareness Month, and timely findings from a study published by Amonoo et al in the journal Blood Advances suggested that, among caregivers of patients undergoing a stem cell transplant, how someone approaches coping can influence the levels of anxiety, depression, and poor...
High Sugar Consumption May Be Linked to Increased Risk of Premature Aging in Pediatric Cancer Survivors
Survivors of pediatric cancer who consumed more total sugar, added sugar, and sugar-sweetened beverages had more aging-related health conditions than survivors who consumed less sugar, according to a new study presented by Lan et al at the American Association for Cancer Research (AACR) Special...
Patients Who Are HIV-Positive and Have Cancer May Have Accelerated Epigenetic Aging
Patients with cancer who are living with the human immunodeficiency virus (HIV) infection had an increased epigenetic age compared with patients with cancer living without the HIV infection, according to a new study presented by Coghill et al at the American Association for Cancer Research (AACR)...
Presence of Tumor-Infiltrating Lymphocytes Following Neoadjuvant Treatment May Contribute to Worse Survival in Patients With HER2-Positive Breast Cancer
Patients with HER2-positive breast cancer may be less likely to survive if their initial treatment fails to eradicate the tumor completely and they have high levels of tumor-infiltrating lymphocytes in their residual tumors, according to a new study published by Miglietta et al in the European...
Intraoperative Ultrasound vs Wire Localization in Surgery for Ductal Carcinoma in Situ
Using intraoperative ultrasound to guide surgery for patients with ductal carcinoma in situ may yield better results than the standard technique of using a wire inserted into the breast, according to a new study published by Esgueva et al in the European Journal of Cancer. The findings were also...
Effect of Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Patients Aged 70 and Older Receiving Treatment for Advanced Cancer
In a secondary analysis of the Geriatric Assessment for Patients 70 Years and Older (GAP70+) trial reported in the Journal of Clinical Oncology, Eva Culakova, PhD, MS, and colleagues found that providing geriatric assessment–based recommendations to community oncologists was associated with reduced ...
Pharmacology Researcher James Turkson, PhD, to Become Director for Diversity, Inclusion, and Strategy at Cedars-Sinai
JAMES TURKSON, PhD, Professor in the Division of Medical Oncology in the Department of Medicine at Cedars-Sinai, is uniquely positioned for a new role developed at Cedars-Sinai Cancer: Director for Diversity, Inclusion, and Strategy. “I have great confidence that Dr. Turkson will provide superb...
C.S. Pramesh, MS, FRCS, Seeks to Bring Equity to India’s Sprawling Cancer Care System
In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with C.S. Pramesh, MS, FRCS, Director of the Tata Memorial Hospital and Professor and Head of Thoracic Surgery at the Tata Memorial Centre, Mumbai, India. Dr. Pramesh is the Convener of the...
Before Becoming a Leader in Multiple Myeloma Research, Sarah A. Holstein, MD, PhD, Considered a Career in Music
Myeloma expert Sarah A. Holstein, MD, PhD, was born and reared in Iowa City, a college town in eastern Iowa along the banks of the Iowa River. “The town itself is small, but it doubles in population when all the college students are present. Both my parents had a PhD in humanities, so I had no...
ASCO Publishes Rapid Guideline Update on PARP Inhibitors in Ovarian Cancer
An ASCO guideline rapid update is revising guidance for the use of poly (ADP-ribose) polymerase (PARP) inhibitor therapy for the management of ovarian cancer to include updated considerations for the use of several different PARP inhibitor therapies based on recent phase III clinical trial data.1...
Expert Point of View: Sanjay Popat, FRCP, PhD
“Adjuvant osimertinib has been adopted widespread as a standard of care as a result of the primary results of ADAURA,” said formal discussant Sanjay Popat, FRCP, PhD, medical oncologist and lung specialist at the Royal Marsden Hospital, NHS Foundation Trust, London. “We have more granularity about ...
Longer-Term Follow-up From ADAURA Supports Adjuvant Osimertinib as Standard of Care for EGFR-Mutated Stage IB to IIIA NSCLC
With longer-term follow-up, adjuvant treatment with osimertinib led to a 77% reduction in the risk of disease recurrence or death following complete resection vs placebo-treated patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer (NSCLC). Disease-free survival was improved...
Building a New Normal: Symptom Self-Management Intervention May Benefit Cancer Survivors
An easy-to-deploy, automated self-management intervention may prove to be of benefit in supporting competence and symptom management among cancer survivors, according to data presented during the 2022 ASCO Quality Care Symposium.1 Analysis of the randomized controlled trial found that 12 months...
New Leadership Elected to the American Society of Hematology
The American Society of Hematology (ASH) recently announced the election of four new members to its Executive Committee for terms beginning after the 2022 ASH Annual Meeting & Exposition in December in New Orleans. Belinda R. Avalos, MD, will serve a 1-year term as Vice President, followed...
Importance of Screening Programs in Diagnosing Cancer in Patients With Type 2 Diabetes
Researchers have discovered that patients with type 2 diabetes who develop cancer are more likely to be diagnosed with advanced disease if they do not undergo routine screenings, according to a new study published by Jansana et al in the European Journal of Cancer. The new findings were also...
Personalized Breast Cancer Screening Model May Improve Outcomes and Reduce Overdiagnosis
Researchers have created a model for predicting an individual’s breast cancer risk that could be used to create personalized breast cancer screening strategies, according to a new study published by Louro et al in the European Journal of Cancer. The research, also presented at the 13th European...
Expert Point of View: Fabrice André, MD, PhD
Fabrice André, MD, PhD, Professor of Medical Oncology at the Gustave Roussy Cancer Center, Villejuif, France, and Chairman of the Biomarker Group at UNICANCER, provided comments on the stage IIA cohort of the PALLAS trial. “The key message from PALLAS1 is there is no signal for efficacy of...
PALLAS Trial: No Benefit Reported for Adjuvant Palbociclib in Stage IIA Hormone Receptor–Positive, HER2-Negative Breast Cancer
In a preplanned analysis of the stage IIA cohort of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone. This finding suggests this agent provides no benefit in reducing the risk of early relapse in patients with ...
UICC Outlines Antimicrobial Resistance in Cancer Treatment
Marking World Antimicrobial Awareness Week (taking place November 18 to 24), the Union for International Cancer Control (UICC) emphasized the danger that drug resistance poses to individuals who are particularly vulnerable to infection, such as people living with cancer. There has been substantial...
The NordICC Trial: The Devil Is in the Details
Colorectal cancer ranks third among cancer deaths in both men and women in the United States, with an estimated 150,000 new cases and 52,000 deaths anticipated in 2022.1 Colorectal cancer rates have declined by approximately 2% per year from 2014 to 2018 in people older than age 50, which is...
How ASCO Is Helping Members Navigate the Cancer Care Terrain for Pregnant Patients Since the Reversal of Roe v Wade
In response to the U.S. Supreme Court decision in Dobbs v Jackson Women’s Health Organization overturning Roe v Wade, eliminating the constitutional right to an abortion and returning the power to regulate reproductive health for women to the states, ASCO, the American Cancer Society Action...
First-Line Maintenance Therapy With Olaparib Improved Outcomes in BRCA-Mutated, HRD-Positive Advanced Ovarian Cancer
First-line maintenance therapy with olaparib extended survival beyond historical expectations in some women with newly diagnosed advanced ovarian cancer, according to long-term follow-up of two phase III studies presented at the European Society for Medical Oncology (ESMO) Congress 2022.1,2 Paul...
Gradual Increase in Daily Activity With Psychological Therapies May Improve Mental and Physical Health for Patients and Survivors of Breast Cancer
Patients and survivors of breast cancer may have better mental health, physical health, and quality of life when taking part in a “behavioral graded activity” in combination with psychological therapies, according to a new study published by Lahousse et al in the European Journal of Cancer. The new ...
FDA Approves New Dosing Regimen for Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn
On November 18, the U.S. Food and Drug Administration (FDA) approved a new Monday/Wednesday/Friday dosing regimen for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze). Under the new regimen, patients should receive 25 mg/m2 intramuscularly on Monday and Wednesday mornings and 50 mg/m2...
Study Examines Potential Factors Leading to Recurrence of Cancers Caused by BRCA Mutations
Researchers have discovered the factors that may make breast and ovarian cancers associated with BRCA1 and BRCA2 gene mutations more likely to recur, according to new findings published by Shah et al in Nature Communications. These mutations are known to strongly predispose women to breast and...
CAR T-Cell Therapy Outcomes Similar Across Different Socioeconomic Levels Among Patients With Pediatric ALL
Although socioeconomic status often influences survival outcomes, pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) who were living in poverty and were treated with CAR T-cell therapy achieved similar overall survival and were equally likely to achieve a complete...
POSEIDON Trial: First-Line Durvalumab With or Without Tremelimumab Plus Chemotherapy in Metastatic NSCLC
As reported in the Journal of Clinical Oncology by Melissa L. Johnson, MD, and colleagues, the pivotal phase III POSEIDON trial has shown significantly improved progression-free and overall survival with the addition of tremelimumab and durvalumab to platinum-based chemotherapy in the first-line...
Dabrafenib in Combination With Trametinib for Unresectable or Metastatic Solid Tumors With BRAF V600E Mutation
On June 22, 2022, dabrafenib in combination with trametinib was granted accelerated approval for treatment of adult and pediatric patients (aged 6 and older) with unresectable or metastatic solid tumors with BRAF V600E mutation whose disease progressed following prior treatment and who have no...
Moderate Exercise May Help Reduce Inflammation, Increase Survival in Patients With Colorectal Cancer by Improving Gut Microbiota
After examining the impact of exercise on the gut microbiome of patients with cancer and reporting a positive association, researchers discovered that regular physical activity may extend the survival of patients with colorectal cancer, according to a new study published by Himbert et al in the...
Study Shows That Immune Cells May Help Identify Patients With High-Risk Smoldering Myeloma Most Likely to Benefit From Treatment
For many patients who have smoldering myeloma, early treatment can slow or delay the disease’s progression to multiple myeloma, according to a new study published by Sklavenitis-Pistofidis et al in Cancer Cell. Investigators demonstrated that changes in immune system cells may indicate which cases...
Randomized Phase II Trial Shows Benefits of Prophylactic Radiation Therapy for Asymptomatic Bone Metastases
The use of prophylactic radiation therapy for patients with metastatic cancer who had asymptomatic, high-risk bone metastases reduced the incidence of skeletal-related events, reduced pain and the number of hospitalizations, and was associated with significantly longer overall survival compared...
Michael A. Postow, MD, on Using the Novel Radiotracer Crefmirlimab Berdoxam for Imaging to Assess Immunotherapy Responsiveness
Michael A. Postow, MD, of Memorial Sloan Kettering Cancer Center, discusses new findings on the correlation between CD8 cell PET imaging with zirconium-89–crefmirlimab berdoxam and CD8 cell immunohistochemistry in patients with advanced cancer receiving immunotherapy. Noninvasive CD8 PET scanning...
2022 State of Lung Cancer Report: Critically Low Lung Cancer Screening Rates Reveal Opportunity to Save More Lives
The 2022 State of Lung Cancer report by the American Lung Association revealed that only 5.8% of eligible Americans had been screened for lung cancer in 2021, and some states had screening rates as low as 1%. The 5th annual report highlighted how the toll of lung cancer varied by state and examined ...
Used as a Biomarker, MicroRNA May Help Predict Which Patients With Breast Cancer Are More Likely to Have Cancer Recurrence
MicroRNA may be used as a biomarker to predict which patients are likely to face breast cancer recurrence and mortality, according to a new study published by Davey et al in the Journal of the American College of Surgeons. While long-term outcomes have improved for patients with breast cancer, 20%...
Talal El Zarif, MD, and Abdul Rafeh Naqash, MD: For Patients Living With HIV and Cancer, New Data on Immune Checkpoint Inhibitors
Talal El Zarif, MD, of Dana-Farber Cancer Institute, and Abdul Rafeh Naqash, MD, of Stephenson Cancer Center at The University of Oklahoma, discuss the results of their cohort study of patients living with HIV and metastatic non–small cell lung cancer, who are often underrepresented in clinical...
